

Dr Jane Steele

Director, Human Biomaterials Resource Centre

Medical and Dental Sciences

Contact details

Telephone **+44 (0)121 414 7668** (tel:+44 121 414 7668)

Email j.c.steele@bham.ac.uk (mailto:j.c.steele@bham.ac.uk)

Human Biomaterials Resource Centre
Medical School
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK



About

Jane obtained a PhD from the University of Bath and worked as a Research Fellow in the UoB CRUK Institute of Cancer Studies for many years before moving to the R&KT office in January 2009.

She is now responsible for the Advanced Therapies Facility (ATF), which houses the Human Biomaterials Resource Centre and both Cell and Gene Therapy manufacturing suites. She is also responsible for providing advice on all aspects of compliance with the Human Tissue Act and the associated Codes of Practice, and for the implementation of Laboratory Good Clinical Practice. A key part of her role is to oversee and contribute to developing research programmes within, or connected to, the ATF and to ensure the facility is at the forefront of technical advances in the field.

Qualifications

- PhD
- BSc (Hons) 2:1

Publications

- **Todd RW, Steele JC, Etherington I, and Luesley DM.** (2004) Detection of CD8+ T cell responses to human papillomavirus (HPV) type 16 antigens in women using imiquimod as a treatment for high grade vulval intraepithelial neoplasia (VIN). *Gynecol. Oncol.* 92(1):167-74
- **Sutton IJ, Steele J, Savage CO, Winer JB, and Young LS.** (2004) An interferon- γ ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. *J. Neuroimmunol.* 150(1-2):98-106
- **Steele JC, Mann CH, Rookes S, Rollason T, Murphy D, Freeth M, Gallimore PH, and Roberts S.** (2005) T-cell responses to human papillomavirus (HPV) type 16 antigens among women with different grades of cervical neoplasia. *Br. J. Cancer* 93(2):248-59
- **Steele JC, Torr E, Noakes KL, Kalk E, Moss PA Reynolds GM, Hubsher SG, van Lohuizen M, Adams DA, and Young LS** (2006) The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. *Br. J. Cancer* 95:1202-11
- **Steele J, Collins S, Wen K, Ryan G, Constandinou-Williams C, and Woodman CB** (2008) Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay. *Clin. Vaccine Immunol.* 15:1387-90
- **Ahmed F, Steele JC, Herbert JM, Steven NM, and Bicknell R** (2008) Tumor stroma as a target in cancer. *Curr. Cancer Drug Targets* 6:447-53
- **Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, and Adams DH** (2009) A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. *Hepatology* 49:124-32
- **Steele JC, Rao A, Armstrong CJ, Berhane S, Billingham LJ, Graham N, Roberts C, Ryan G, Uppal H, Walker C, Young LS, and Steven NM** (2011) Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. *Gene Therapy*(in press).